Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CRHBP | P24387 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 4/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21253230 | 0.98 | MEN1 (0.39) | MEN1KMT2ALMNAHPGDCRHBP | |
| SCHEMBL21259095 | 0.96 | MEN1 (0.41) | MEN1KMT2ALMNAHPGDCRHBP | |
| SCHEMBL21247144 | 0.89 | MEN1 (0.41) | MEN1KMT2ALMNAHPGDCRHBP | |
| SCHEMBL21247335 | 0.86 | NAMPT (0.42) | MEN1KMT2ALMNAHPGDCRHBP | |
| SCHEMBL21250162 | 0.85 | MEN1 (0.39) | MEN1KMT2ALMNAHPGDCRHBP | |
| SCHEMBL22699621 | 0.85 | CNR2 (0.31) | EPHX2TTK | |
| SCHEMBL21253167 | 0.84 | MEN1 (0.60) | MEN1KMT2ALMNAHPGDCRHBP | |
| SCHEMBL21259098 | 0.83 | GRIN2C (0.44) | MEN1KMT2ALMNAHPGDCRHBP | |
| SCHEMBL23263119 | 0.82 | MEN1 (0.44) | MEN1KMT2ALMNAHPGDCRHBP | |
| SCHEMBL21253125 | 0.80 | HDAC8 (0.46) | MEN1KMT2ALMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | claimed |
| EP-3749649-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | claimed |
| US-20200369655-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | claimed |
| WO-2019154953-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | claimed |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | ENYO PHARMA (FR) | 2023-10-12 | — | — | US | disclosed |
| WO-2021074357-A1 | THIOPHENE DERIVATIVES FOR USE IN TREATING PORTAL INFLAMMATION AND FIBROSIS | ENYO PHARMA (FR) | 2021-04-22 | — | — | WO | disclosed |
| EP-3749649-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369655-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| US-20200369655-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| WO-2019154953-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154953-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369655-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | MEN1 3578/4885KMT2A 3273/4885LMNA 4792/4885 |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | MEN1 3578/4885KMT2A 3273/4885LMNA 4792/4885 |
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | TST, TPMT, MMP1 | MEN1 4395/4885KMT2A 2985/4885LMNA 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.